Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,595.50
Bid: 1,595.50
Ask: 1,596.00
Change: -13.00 (-0.81%)
Spread: 0.50 (0.031%)
Open: 1,604.50
High: 1,609.00
Low: 1,594.50
Prev. Close: 1,608.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of GSK 2019 Form 20-F

9 Mar 2020 07:00

RNS Number : 3525F
GlaxoSmithKline PLC
09 March 2020
 

 

GlaxoSmithKline plcAnnual Report 2019 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 06 March 2020 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2019. GSK's 2019 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the GSK 2019 Annual Report, together with the Notice of Annual General Meeting will be available on or about 23 March 2020.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2020, free of charge, by either:

(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the US); or

(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

Victoria WhyteCompany Secretary06 March 2020

 

Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2019.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKABDDBKBONK
Date   Source Headline
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:00 pmRNSTotal Voting Rights
22nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
21st Dec 20223:35 pmRNSDirector/PDMR Shareholding
21st Dec 20223:30 pmRNSDirector/PDMR Shareholding
15th Dec 20223:30 pmRNSBoard and Committee Changes
13th Dec 20223:30 pmRNSDirector/PDMR Shareholding
7th Dec 20227:00 amRNSStatement: Zantac (ranitidine) litigation
5th Dec 20224:00 pmRNSTransfer of Treasury Shares
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
25th Nov 20224:47 pmRNSPublication of Final Terms of EMTN Notes
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.